SSY Group Limited (the “Group”) has received production and registration approval from China’s National Medical Products Administration for its 135 mg Choline Fenofibrate Sustained-release Capsules, classified as a type 4 chemical drug and deemed to have passed the national consistency evaluation.
The new formulation targets adults on controlled diets who need to lower triglyceride levels in severe hypertriglyceridemia or who require treatment for primary hypercholesterolemia and mixed dyslipidemia. Compared with traditional fenofibrate, the choline salt form offers direct pharmacological action, reduced liver and kidney burden, no dietary restrictions, and safe co-administration with statins, positioning it as a high-end, next-generation lipid-lowering therapy with clear clinical value.
Management highlighted the milestone as a significant product development for the Group’s portfolio. The disclosure is voluntary and intends to update shareholders and potential investors on the latest business progress.
The announcement was authorised by the Board of SSY Group Limited and dated 16 July 2026.
Comments